'김갑성' 기자의 전체기사
-
Plasmatreat Introduces HydroPlasma®: 高性能表面洗浄における持続…
ドイツ・シュタインハーゲン, 2025年7月26日 -- 大気圧プラズマ技術の世界的リーダーであるPlasmatreat GmbHは、ガラスや金属表面を超高精度で洗浄する革新的かつ環境に優しいソリューションHydroPlasma®を発表しました。Openair-Plasma®の実証された効果とイオン化水の反応力を組み合わせた HydroPlasma®は、指紋、油分、塩分、グリースなどの頑固な有機・無機汚染物を化学薬品を使わずに除去する新たな基準を打ち立てます。 ハイテク産業とプロセスにおける洗浄の革命 自動車、電子機器、航空宇宙、医療機器製造などの分野では、微細な汚染物でさえ、接着、コーティング、印刷、シーリングといった重要な工程での密着性を損なう可能性があります。従来の洗浄方法は溶剤や湿式化学処理に頼ることが多いですが、HydroPlasma® は圧縮空気、電気、水のみを使用し、化学薬品を使わない持続可能な代替手段を提供します。この先進技術は、洗浄効率を高めるだけでなく、環境に配慮した生産活動も支援します。 HydroPlasma®の仕組み：科学と持続可能性の融合 HydroPlasma®の特許取得済みプロセ
- 김갑성 기자
- 2025-07-28 15:03
-
플라스마트리트, 하이드로플라스마® 출시… 고성능 표면 세척 위한 지속 가능한 신기술
슈타인하겐, 독일, 2025년 7월 26일 -- 대기 플라스마 기술 분야의 글로벌 선도 기업 플라스마트리트 유한책임회사(Plasmatreat GmbH)가 유리 및 금속 표면의 초정밀 세척을 위한 혁신적이고 친환경적인 솔루션 하이드로플라스마(HydroPlasma®)를 출시했다. 오픈에어 플라스마(Openair-Plasma®)의 검증된 효능에 이온화된 물의 반응성을 결합한 하이드로플라스마®는 지문, 기름, 염분, 그리스 등 제거가 까다로운 유기 및 무기 오염 물질을 화학 약품 없이 제거함으로써 세정 기술의 새로운 기준을 제시하고 있다. 하이테크 산업 및 공정의 세정 혁신 자동차, 전자, 항공우주, 의료 제조 등 다양한 산업 분야에서는 미세한 오염 물질조차도 접착, 코팅, 인쇄, 밀봉 등 주요 공정에서 접착력에 영향을 줄 수 있다. 기존 세정 방식은 일반적으로 용제나 습식 화학 처리에 의존해 왔으나 하이드로플라스마®는 압축 공기, 전기, 물만을 사용해 화학 물질 없이 지속 가능한 대안을 제공한다. 이 첨단 기술은 세정 효율을 높이는 동시에 친환경적인
- 김갑성 기자
- 2025-07-28 15:03
-
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosim…
[ 메디채널 김갑성 기자 ] CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® biosimilar by Alteogen's license partner Qilu Pharmaceutical DAEJEON, South Korea, July 28, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI® (code name: ALT-L9), a bi
- 김갑성 기자
- 2025-07-28 14:00
-
MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALA…
KUALA LUMPUR, Malaysia, July 28, 2025 -- The Malaysia Healthcare Travel Council (MHTC) launched Malaysia Year of Medical Tourism (MYMT) 2026 at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health Malaysia, officiated the event, unveiling the campaign's logo and tagline, "Healing Meets Hospitality." MYMT 2026 aims to position Malaysia as a premier medical tourism destination by showcasing its advanced healthcare services and hospitality. The campaign also seeks to attract international heal
- 김갑성 기자
- 2025-07-28 12:17
-
NMPA Accepts sNDA for Ivonescimab in Combination with Chem…
HONG KONG, July 28, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). This submission represents the third accepted application for ivonescimab in China, following previous filings for its combination therapy in EGFR-TKI resistant locally advanced or metasta
- 김갑성 기자
- 2025-07-28 12:14
-
Antengene Announces Poster Presentation of ATG-022 (Clau…
SHANGHAI and HONG KONG, July 28, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17t
- 김갑성 기자
- 2025-07-28 10:40
-
Antengene Announces XPOVIO® Approved in China for the Se…
This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug in China. XPOVIO® as a monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and in combination with dexamethasone in patients with R/R MM, two of the three approved indications of XPOVIO® in China, have already been included into China's National Reimbursement Drug List. Results from the BENCH
- 김갑성 기자
- 2025-07-28 10:35
-
Ascletis Announces First Participants with Obesity or Overweig…
- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous (SQ) depot formulation of small molecule GLP-1 receptor agonist ASC30. - Ultra-long-acting SQ depot formulation of small molecule ASC30 demonstrated a 36-day half-life in participants with obesity in the Phase Ib study, supporting once monthly administration. - Phase Ib study also demonstrated that compared to the trough concentration of ASC30 at Day 29, the ultra-long-acting SQ d
- 김갑성 기자
- 2025-07-28 08:15
-
Harbour BioMed Announces Positive Profit Alert for 2025 Interim R…
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 28, 2025 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the six months ended June 30, 2025 (the "Reporting Period"). Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, total profit is expected to range between US$68 million (equivalent to approximately HK$53
- 김갑성 기자
- 2025-07-28 08:11
-
AESTURA, Korea's #1 Dermatologist-Recommended Dermocos…
[ 메디채널 김갑성 기자 ] Premium dermocosmetic brand specialising in sensitive skin launches from August 26th, bringing clinically-proven innovation to Australian skincare market SYDNEY, July 28, 2025 -- AESTURA, Korea's #1 dermatologist-recommended dermocosmetic brand for sensitive skin[1], breaks new ground in the Australian skincare market with its exclusive launch at Sephora Australia stores and on Sephora.com.au, beginning August 26th, 2025. This strategic partnership with Sephora Australia answers the growing demand for advanced, science-backed solutions in the dermatologist skincare ca
- 김갑성 기자
- 2025-07-28 08:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-25_SAT
- PINTEC Announces Changes in the Board of Directors 04:30
- MindHYVE.ai™ and Prime Institute of Health Sciences (PIHS) Launch Landmark AI Partnership to Transform Education and Healthcare in Pakistan 02:18
- Freedom Engineered: QUINEAR QN-090A Redefines Smart, Cordless Recovery -- Just in Time for Holiday Season 00:10
- Beyond Recovery: QUINEAR QN-071A Brings Professional Compression Therapy Home for Holiday Deals 00:07
2025-10-24_FRI
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 25일 06시 00분